(Q33500910)

27 July 2017

1 reference

title

Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode (English)

1 reference

27 July 2017

0 references

D S Goodin

1

1 reference

27 July 2017

D Bates

series ordinal

2

1 reference

27 July 2017

publication date

1 October 2009

1 reference

Multiple Sclerosis Journal

27 July 2017

published in

1 reference

27 July 2017

volume

15

1 reference

27 July 2017

issue

10

1 reference

27 July 2017

page(s)

1175-1182

1 reference

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Glatiramer acetate in multiple sclerosis: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Axonal damage in acute multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Natural history of multiple sclerosis: a unifying concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509107007

21 January 2018

Identifiers

DOI

10.1177/1352458509107007

1 reference

27 July 2017

1 reference